Intraglandular botulinum neurotoxin (BoNT) injection vs placebo injection
Reduction in frequency and severity of drooling · Adults with Parkinson's disease and sialorrhea (drooling)
Type A botulinum toxin significantly reduced DSFS scores versus placebo (SMD -0.80, 95% CI -1.25 to -0.36; ungraded subgroup).
3 findings from 1 review
- The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's disease: a… 2023 All outcomesApproximately 1 month post-injection (one study ~1 week) · Movement-disorder / neurology outpatient care (trials from Italy, USA, and Estonia) · BoNT type ASMD -0.80 [-1.25, -0.36]4 studies · 88 participantsGRADE not reported
- The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's disease: a… 2023 All outcomesApproximately 1 month post-injection (one study ~1 week) · Movement-disorder / neurology outpatient care (trials from Italy, USA, and Estonia) · BoNT type BSMD -1.11 [-1.48, -0.74]5 studies · 136 participantsGRADE not reported
- The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's disease: a… 2023 All outcomesApproximately 1 month post-injection (one study ~1 week) · Movement-disorder / neurology outpatient care (trials from Italy, USA, and Estonia)SMD -0.98 [-1.27, -0.70]9 studies · 224 participantsHigh